Platinum-Doublet Chemotherapy
Showing 1 - 25 of >10,000
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer Trial in Orlando, Albuquerque
Recruiting
- Platinum-resistant Ovarian Cancer
- +6 more
- olvimulogene nanivacirepvec
- +3 more
-
Orlando, FloridaAdventHealth Cancer Institute
Sep 1, 2022
NSCLC Trial in Tianjing (Envalfolimab subcutaneously injected+Platinum-based doublet chemo intravenous injection,
Not yet recruiting
- Non-small Cell Lung Cancer
- Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
- placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection
-
Tianjing, Tianjin, ChinaTianjin cancer hospital
Nov 3, 2023
NSCLC, Stage III Trial in Beijing (Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC),
Recruiting
- NSCLC, Stage III
- Tislelizumab
- +2 more
-
Beijing, Beijing, ChinaBeijing Tsinghua Chang Gung Hospital
Nov 4, 2022
Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung
Not yet recruiting
- Advanced Non-squamous Non-small-cell Lung Cancer
- +2 more
- pembrolizumab
- +2 more
-
Beijing, Beijing, ChinaPeking University First Hospital Ethics Committee
Sep 10, 2023
NSCLC (NSCLC) Trial (Ociperlimab, Placebo, Tislelizumab)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Ociperlimab
- +8 more
- (no location specified)
Mar 17, 2023
NSCLC Trial in Philadelphia (device, drug, other)
Not yet recruiting
- NSCLC
- Aliya Pulsed Electric Fields (PEF) ablation
- +3 more
-
Philadelphia, PennsylvaniaTemple University
Oct 24, 2022
Non Small Cell Lung Cancer Metastatic Trial (Pembrolizumab in Combination with Plinabulin and Docetaxel)
Not yet recruiting
- Non Small Cell Lung Cancer Metastatic
- Pembrolizumab in Combination with Plinabulin and Docetaxel
- (no location specified)
Oct 28, 2022
Non Small Cell Lung Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitor Trial in Beijing (Pembrolizumab)
Recruiting
- Non Small Cell Lung Cancer
- +2 more
-
Beijing, ChinaPeking Union Medical College Hospital
May 17, 2022
Stage II-III NSCLC Trial in Shanghai (4cycles(Toripalimab IV 240mg + platinum-based doublet chemo)+13 cycles(Toripalimab IV
Recruiting
- Stage II-III Non-small Cell Lung Cancer
- 4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab
- 4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )
-
Shanghai, ChinaShanghai Chest Hospital
Apr 12, 2022
Locally Advanced, NSCLC Trial in Shanghai (drug, procedure, radiation)
Recruiting
- Locally Advanced
- Non-small Cell Lung Cancer
- Serplulimab
- +5 more
-
Shanghai, ChinaShanghai Pulmonary Hospital
Mar 14, 2023
Stage III NSCLC Trial (Toripalimab, JS004, Pemetrexed)
Not yet recruiting
- Stage III Non-small Cell Lung Cancer
- Toripalimab
- +5 more
- (no location specified)
Jun 3, 2023
Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced Trial in Beijing
Not yet recruiting
- Mesothelioma, Malignant
- +2 more
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Dec 27, 2021
Non-small-cell Lung Cancer Patients Trial in Roma (Durvalumab, Olaparib tablet, Single-agent chemo)
Recruiting
- Non-small-cell Lung Cancer Patients
- Durvalumab
- +3 more
-
Roma, RM, ItalyIstituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena
Sep 30, 2022
Limited Stage Small Cell Lung Cancer Trial in Shang'ai (chemo and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy)
Not yet recruiting
- Limited Stage Small Cell Lung Cancer
- chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy
-
Shang'ai, Shanghai, ChinaShanghai Pulmonary Hospital
Aug 8, 2022
NSCLC Trial in Saint Petersburg, Cremona, Vilnius (REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab)
Terminated
- Non-small Cell Lung Cancer
- REGN2810/ipi
- +2 more
-
Saint Petersburg, Florida
- +2 more
Oct 22, 2022
Non Small Cell Lung Cancer Trial in Xi'an (Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound)
Recruiting
- Non Small Cell Lung Cancer
- Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin
-
Xi'an, Shaanxi, ChinaTangDu hospital, the Airforce Military Medical University
Apr 19, 2021
Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC
Recruiting
- Non-Small Cell Lung Cancer
- Neoadjuvant immunochemotherapy
- Neoadjuvant chemotherapy
-
Beijing, Beijing, ChinaNational Cancer Center/Cancer Hospital,Chinese Academy of Medica
Aug 1, 2023
Tumors, Metastatic Cancer, Advanced Cancer Trial in United States (Niraparib, TSR-042, Carboplatin-Paclitaxel)
Head Neck Cancer, Head Cancer, Head Cancer Neck Trial in United States (drug, procedure, radiation)
Recruiting
- Head and Neck Cancer
- +5 more
- Cisplatin
- +6 more
-
Basking Ridge, New Jersey
- +5 more
Jan 19, 2023
Metastatic Non Small Cell Lung Cancer Trial in Nicosia (Pembrolizumab)
Unknown status
- Metastatic Non Small Cell Lung Cancer
-
Nicosia, Strovolos, CyprusBank of Cyprus Oncology Centre
Jan 26, 2021